Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/114088
PIRA download icon_1.1View/Download Full Text
DC FieldValueLanguage
dc.contributorDepartment of Applied Biology and Chemical Technologyen_US
dc.creatorZheng, Yen_US
dc.creatorKan, CHen_US
dc.creatorTsang, TFen_US
dc.creatorLiu, Yen_US
dc.creatorLiu, Ten_US
dc.creatorTsang, MWen_US
dc.creatorLam, LYen_US
dc.creatorYang, Xen_US
dc.creatorMa, Cen_US
dc.date.accessioned2025-07-11T09:11:32Z-
dc.date.available2025-07-11T09:11:32Z-
dc.identifier.issn0022-2623en_US
dc.identifier.urihttp://hdl.handle.net/10397/114088-
dc.language.isoenen_US
dc.publisherAmerican Chemical Societyen_US
dc.rights© 2024 American Chemical Societyen_US
dc.rightsThis document is the Accepted Manuscript version of a Published Work that appeared in final form in Journal of Medicinal Chemistry, copyright © 2024 American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see https://doi.org/10.1021/acs.jmedchem.4c01386.en_US
dc.titleDiscovery of inhibitors targeting protein-protein interaction between bacterial RNA polymerase and NusG as novel antimicrobialsen_US
dc.typeJournal/Magazine Articleen_US
dc.identifier.spage16556en_US
dc.identifier.epage16575en_US
dc.identifier.volume67en_US
dc.identifier.issue18en_US
dc.identifier.doi10.1021/acs.jmedchem.4c01386en_US
dcterms.abstractBacterial RNA polymerase (RNAP), the core enzyme responsible for bacterial transcription, requires the NusG factor for efficient transcription elongation and termination. As the primary binding site for NusG, the RNAP clamp-helix (CH) domain represents a potential protein-protein interaction (PPI) target for novel antimicrobial agent design and discovery. In this study, we designed a pharmacophore model based on the essential amino acids of the CH for binding to NusG, such as R270, R278, and R281 (Escherichia coli numbering), and identified a hit compound with mild antimicrobial activity. Subsequent rational design and synthesis of this hit compound led to improved antimicrobial activity against Streptococcus pneumoniae, with the minimum inhibitory concentration (MIC) reduced from 128 to 1 μg/mL. Additional characterization of the antimicrobial activity, inhibitory activity against RNAP-NusG interaction, and cell-based transcription and fluorescent assays of the optimized compounds demonstrated their potential for further lead optimization.en_US
dcterms.accessRightsopen accessen_US
dcterms.bibliographicCitationJournal of medicinal chemistry, 26 Sept 2024, v. 67, no. 18, p. 16556-16575en_US
dcterms.isPartOfJournal of medicinal chemistryen_US
dcterms.issued2024-09-26-
dc.identifier.scopus2-s2.0-85202782566-
dc.identifier.eissn1520-4804en_US
dc.description.validate202507 bcchen_US
dc.description.oaAccepted Manuscripten_US
dc.identifier.FolderNumbera3854c-
dc.identifier.SubFormID51387-
dc.description.fundingSourceRGCen_US
dc.description.fundingSourceOthersen_US
dc.description.fundingTextHong Kong Polytechnic Universityen_US
dc.description.pubStatusPublisheden_US
dc.description.oaCategoryGreen (AAM)en_US
Appears in Collections:Journal/Magazine Article
Files in This Item:
File Description SizeFormat 
Zheng_Discovery_Inhibitors_Targeting.pdfPre-Published version2.76 MBAdobe PDFView/Open
Open Access Information
Status open access
File Version Final Accepted Manuscript
Access
View full-text via PolyU eLinks SFX Query
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.